Disease · MONDO_0005089
sarcoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. sarcoma. Diseases, record MONDO_0005089. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005089
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- mesenchymal tumor, malignant, sarcoma of soft tissue and bone, sarcoma of the soft tissue and bone, sarcoma, malignant, tumor of soft tissue and skeleton
- Open Targets
- Highest stage of its drugs
- Approval, for 6 of its 179 drugs, from DailyMed, EMA Human Drugs and FDA
- Open Targets
Drugs179
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TRABECTEDIN | CHEMBL450449 | Small molecule | Approval | EMA Human Drugs | 8 | 5 | 5 | Drugs and targets |
| DOXORUBICIN HYDROCHLORIDE | CHEMBL359744 | Small molecule | Approval | DailyMed | 5 | 3 | 3 | Drugs and targets |
| OLARATUMAB | CHEMBL1743049 | Antibody | Approval | DailyMed and FDA | 3 | 0 | 0 | Drugs and targets |
| PAZOPANIB HYDROCHLORIDE | CHEMBL1201733 | Small molecule | Approval | DailyMed and FDA | 2 | 0 | 0 | Drugs and targets |
| TASONERMIN | CHEMBL2107891 | Protein | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| TAZEMETOSTAT HYDROBROMIDE | CHEMBL4594260 | Small molecule | Approval | FDA | 1 | 0 | 0 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 20 | 20 | 20 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| IPILIMUMAB | CHEMBL1789844 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
1 to 10 of 179
See all 179 drugsTargets262
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 11 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3791 | Drugs and targets |
| TUBB | Tubulin | 10 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/203068 | Drugs and targets |
| TUBB1 | Tubulin | 10 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/81027 | Drugs and targets |
| TUBB2A | Tubulin | 10 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7280 | Drugs and targets |
| TUBB2B | Tubulin | 10 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/347733 | Drugs and targets |
| TUBB3 | Tubulin | 10 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10381 | Drugs and targets |
| TUBB4A | Tubulin | 10 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10382 | Drugs and targets |
| TUBB4B | Tubulin | 10 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10383 | Drugs and targets |
| TUBB6 | Tubulin | 10 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84617 | Drugs and targets |
| TUBB8 | Tubulin | 10 | Tubulin beta inhibitor; Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/347688 | Drugs and targets |
1 to 10 of 262
See all 262 targetsTrials150
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | Phase 2 | 366 | 2018-11-23 | Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's, Sarcoma, Alveolar Soft Part, Chordoma, Epithelioid Sarcoma, Giant Cell Tumor of Bone, Hemangiopericytoma, Gastrointestinal Stromal Tumor (GIST) | DASATINIB ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | Phase 2 | 164 | 2020-06-16 | Locally Advanced Bone Sarcoma, Locally Advanced Dedifferentiated Liposarcoma, Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Pleomorphic Liposarcoma, Stage III Bone Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Bone Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Bone Sarcoma AJCC v7, Stage IVB Bone Sarcoma AJCC v7, Unresectable Bone Sarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Liposarcoma, Unresectable Malignant Gastrointestinal Stromal Tumor, Unresectable Soft Tissue Sarcoma | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | Phase 1/2 | 151 | 2020-03-03 | High Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Myxofibrosarcoma, Recurrent Leiomyosarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Synovial Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma | SAPANISERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT00245102 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | Phase 2 | 147 | 2014-01-20 | Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Malignant Fibrous Histiocytoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma | SORAFENIB TOSYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT02573259 | A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | Phase 1 | 147 | 2021-12-13 | Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA | SASANLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00560235 | Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors | Phase 1/2 | 138 | 2014-02-28 | Ewing's Sarcoma Family of Tumors | FIGITUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02406781 | Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial | Phase 2 | 129 | 2025-12-10 | Sarcoma | CYCLOPHOSPHAMIDE, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | Phase 1/2 | 89 | 2024-08-20 | Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Solid Tumors | CONATUMUMAB, GANITUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | Phase 1/2 | 78 | 2016-07-22 | Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Unclassified Pleomorphic Sarcoma, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Conjunctival Kaposi Sarcoma, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Kaposi Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Corpus Sarcoma, Small Intestine Leiomyosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Unclassified Pleomorphic Sarcoma of Bone | RG-4733, VISMODEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | Phase 1/2 | 64 | 2023-03-08 | Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma | BEMPEGALDESLEUKIN, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 150
See all 150 trialsComparisons in its trials31
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Phase II - Analysis Group 2 MLN0128 vs Phase II - Analysis Group 2 Pazopanib: Number of Patients Having CR, PR, or SD at 6 Months (Phase II Analysis Group 2 - Initial Treatment Period) | 1 of 56 | 5 of 58 | 114 | NCT02601209 | Trial comparisons |
| Phase II - Analysis Group 2 MLN0128 vs Phase II - Analysis Group 2 Pazopanib: The Number of Patients Who Experienced Grade 3+ Adverse Events (Phase II Analysis Group 2 - Initial Treatment Period) | 28 of 55 | 38 of 56 | 111 | NCT02601209 | Trial comparisons |
| Gemcitabine, Docetaxel, Bevacizumab vs Gemcitabine, Docetaxel, Placebo: serious adverse events | 12 of 37 | 6 of 10 | 47 | NCT00887809 | Trial comparisons |
| Docetaxel + Gemcitabine + Pegfilgrastim + Vorinostat 300 mg/Day vs Docetaxel + Gemcitabine + Pegfilgrastim + Vorinostat 200 mg Twice/Day: deaths from any cause | 26 of 31 | 5 of 6 | 37 | NCT01879085 | Trial comparisons |
| Docetaxel + Gemcitabine + Pegfilgrastim + Vorinostat 300 mg/Day vs Docetaxel + Gemcitabine + Pegfilgrastim + Vorinostat 200 mg Twice/Day: serious adverse events | 19 of 31 | 3 of 6 | 37 | NCT01879085 | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | 10 of 16 | 5 of 13 | 29 | NCT04076579 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 2 of 16 | 4 of 13 | 29 | NCT04076579 | Trial comparisons |
| Cohort 1 vs Cohort 2: Overall Response Rate | 0 of 16 | 2 of 12 | 28 | NCT04076579 | Trial comparisons |
| Cohort 1/Vaccine Plus Chemotherapy vs Cohort 2/Vaccine Alone: Number of Participants With an Immunologic Responses | 4 of 10 | 4 of 11 | 21 | NCT02054104 | Trial comparisons |
Cohort 1/Vaccine Plus Chemotherapy vs Cohort 2/Vaccine Alone: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) | 8 of 10 | 6 of 11 | 21 | NCT02054104 | Trial comparisons |
1 to 10 of 31
See all 31 comparisons in its trialsPapers from its trials98
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005089
GET https://conductscience.org/api/diseases/v1/MONDO_0005089/drugs?page=2